Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock (NQ:CYCCP)

4.802 +0.002 (+0.04%)
Streaming Delayed Price Updated: 10:21 AM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

< Previous 1 2 3 Next >
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients 
From Cyclacel
Via GlobeNewswire
Cyclacel Hosting Research & Development Day
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - 
From Cyclacel
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Epizyme (NASDAQ:EPZM) stock increased by 14.2% to $1.41 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 9.6... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's stock is trading at a volume of 116.0 million... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) shares moved upwards by 33.66% to $4.3 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 87.6... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Organovo Holdings (NASDAQ:ONVO) stock moved upwards by 28.66% to $10.01 during Friday's regular session. Trading volume for this security as of 12:30 EST is 6.... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Gracell Biotechnologies (NASDAQ:GRCL) shares rose 21.25% to $17.69 during Friday's regular session. Trading volume for Gracell Biotechnologies's stock is... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Lianluo Smart (NASDAQ:LLIT) stock rose 35.13% to $10.0 during Wednesday's regular session. Lianluo Smart's stock is trading at a volume of 4.6 million... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.